GSK continues to grow its manufacturing footprint in Singapore with the opening of a new 44 million Singapore dollar ($33 million) (PDF) plant that will be focused on producing key ingredients used for cancer treatments.
The facility is located in Jurong, Singapore, and will make a cytotoxic component for antibody-drug conjugates to treat cancer, the company said in a Nov. 17 press release.
The plant, which the company says is the first of its kind in Singapore, was designed to aid in complete in-house manufacturing for secure supply chain processes, quality control and timeliness of delivery. The facility can also handle high-potency manufacturing.
“With new capabilities to handle high-potency components effectively, we are in a good position to explore new frontiers in oncology and embark on a new era of manufacturing and delivering breakthrough cancer treatments,” Regis Simard, president of GSK’s global supply chain, said in the press release.
In 2015, the global drugmaker began construction of a facility in Singapore to house its Asia pharmaceutical, consumer health care and vaccine businesses. In 2019, the company opened its $95 million continuous manufacturing facility.